文献速递遗传性与小管间质肾病

CDK4/6抑制剂阿贝西利在ADPKD临床前模型中阻止并逆转肾囊肿进展

CDK4/6 Inhibitor Abemaciclib Arrests and Reverses Kidney Cyst Progression in Preclinical Models of Autosomal Dominant Polycystic Kidney Disease.
PubMed 文献 · J Am Soc Nephrol · 2026-09-14

该研究在ADPKD临床前模型中测试CDK4/6抑制剂阿贝西利,发现其低剂量即可抑制囊肿生长,早期长期治疗比托伐普坦更有效且无毒性,晚期干预在雌雄小鼠中分别阻止或逆转囊肿进展,机制与恢复轴丝多聚谷氨酰化和增加纤毛多囊蛋白水平相关。

要点

  • 阿贝西利在低于肿瘤剂量下即可强效抑制ADPKD囊肿生长。
  • 早期长期阿贝西利治疗比托伐普坦更有效且未检测到毒性。
  • 晚期干预在雌性中阻止囊肿生长,在雄性中逆转囊肿进展。

核心结论

  • 阿贝西利在该ADPKD临床前模型中疗效和耐受性优于托伐普坦。
  • 其作用主要由CDK6抑制介导的轴丝多聚谷氨酰化恢复和纤毛多囊蛋白增加驱动。

研究设计与样本

  • 研究采用体外3D囊肿实验和离体后肾器官培养测试阿贝西利。
  • 体内实验在F1(129/B6) Pkd1R3277C/R3277C小鼠中评估早期和晚期每日阿贝西利干预,托伐普坦作为治疗对照。

主要发现

  • CDK6在人及小鼠PKD肾脏的囊衬细胞中显著上调。
  • 阿贝西利在远低于肿瘤学剂量下强效抑制体外和离体囊肿生长。
  • 早期长期治疗比托伐普坦更有效阻止囊肿进展且未检测到毒性。
  • 晚期干预在雌性中基本阻止囊肿生长,在雄性中逆转囊肿进展。
  • 机制上阿贝西利恢复轴丝多聚谷氨酰化并增加纤毛多囊蛋白水平。

临床怎么用

  • 该结果为ADPKD提供CDK4/6抑制剂阿贝西利的临床前证据,支持进一步临床转化研究。

局限性

  • 研究仅为临床前模型,尚未在人体中验证疗效和安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited disorder leading to kidney failure. Tolvaptan, the only FDA-approved therapy, modestly slows disease progression but is limited by significant adverse effects, highlighting the need for more effective and better-tolerated treatments. Ciliary polycystins are central to ADPKD pathogenesis. We previously demonstrated that a cilia base-localized pool of CDK6 restricts ciliary polycystin abundance by suppressing axonemal polyglutamylation. However, whether CDK6 inhibition can restore polycystin function and suppress ADPKD progression in vivo remains unknown. METHODS: Abemaciclib was tested in in vitro 3D cyst assays and ex vivo metanephric organ cultures. In vivo efficacy of early- and late-stage intervention were assessed in F1(129/B6) Pkd1R3277C/R3277C mice receiving daily abemaciclib. Tolvaptan served as a therapeutic control. Cyst burden, fibrosis in the kidneys, kidney function, and primary cilia of renal epithelial cells were analyzed at study endpoints. RESULTS: CDK6 was prominently upregulated in cyst-lining cells in human and murine PKD kidneys. At doses substantially lower than those used in oncology, abemaciclib robustly suppressed cyst growth in vitro and ex vivo. In vivo, long-term early treatment arrested cyst progression more effectively than tolvaptan without detectable toxicity. Late intervention largely halted cyst growth in females and reversed cyst progression in males. Mechanistically, abemaciclib restored axonemal polyglutamylation and increased ciliary polycystin levels. CONCLUSIONS: Abemaciclib has greater therapeutic efficacy and tolerability than tolvaptan in this preclinical model, largely driven by CDK6 inhibition-mediated restoration of axonemal polyglutamylation and increased ciliary polycystin abundance.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Cao Y, Sun X, Huang Y, et al. CDK4/6 Inhibitor Abemaciclib Arrests and Reverses Kidney Cyst Progression in Preclinical Models of Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2026. PMID: 42735034. doi:10.1681/ASN.0000001269

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。